BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21633300)

  • 1. Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
    Magazzino F; Katsaros D; Ottaiano A; Gadducci A; Pisano C; Sorio R; Rabaiotti E; Scambia G; Cormio G; Scarampi L; Greggi S; Savarese A; Marinaccio M; Scollo P; Pignata S
    Int J Gynecol Cancer; 2011 Aug; 21(6):1063-70. PubMed ID: 21633300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
    Esposito F; Cecere SC; Magazzino F; Katsaros D; Ottaiano A; Gadducci A; Pisano C; Scalone S; Rabaiotti E; Salutari V; Cormio G; Canuto EM; Greggi S; Savarese A; Marinaccio M; Scollo P; Santeufemia DA; Sacco C; Facchini G; Pignata S
    Oncology; 2014; 86(5-6):351-8. PubMed ID: 24942520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
    Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
    Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
    Kuku S; Williams M; McCormack M
    Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.
    Hoskins PJ; Le N; Gilks B; Tinker A; Santos J; Wong F; Swenerton KD
    J Clin Oncol; 2012 May; 30(14):1656-62. PubMed ID: 22493415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
    Prendergast EN; Holzapfel M; Mueller JJ; Leitao MM; Gunderson CC; Moore KN; Erickson BK; Leath CA; Diaz Moore ES; Cohen JG; Walsh CS
    Gynecol Oncol; 2017 Feb; 144(2):274-278. PubMed ID: 27979319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
    Shaboodien R; Diamantis N; Blagden S; Gabra H; Agarwal R
    Int J Gynecol Cancer; 2013 Mar; 23(3):481-7. PubMed ID: 23392404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and toxicity between radiotherapy and chemotherapy in nodal and isolated nonnodal recurrence of ovarian cancer.
    Lee M; Kim SW; Lee SH; Paek J; Yim GW; Kim GE; Kim S; Kim JH; Kim YT; Nam EJ
    Int J Gynecol Cancer; 2011 Aug; 21(6):1032-9. PubMed ID: 21738040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).
    Sakuragi N; Yamada H; Oikawa M; Okuyama K; Fujino T; Sagawa T; Fujimoto S
    Gynecol Oncol; 2000 Nov; 79(2):251-5. PubMed ID: 11063653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pure and mixed-type clear cell carcinoma of the ovary: a clinicopathological analysis of 341 Chinese patients.
    Ye S; You Y; Yang J; Cao D; Bai H; Huang H; Wu M; Chen J; Lang J; Shen K
    Int J Gynecol Cancer; 2014 Nov; 24(9):1590-6. PubMed ID: 25254564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
    Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
    Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma.
    Hogen L; Vicus D; Ferguson SE; Gien LT; Nofech-Mozes S; Lennox GK; Bernardini MQ
    Int J Gynecol Cancer; 2019 Sep; 29(7):1164-1169. PubMed ID: 31273067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea.
    Lee HY; Hong JH; Byun JH; Kim HJ; Baek SK; Kim JY; Kim KH; Yun J; Kim JA; Park K; Lee HJ; Lee JL; Won YW; Kim IH; Bae WK; Park KH; Sun DS; Lee S; Lee MY; Lee GJ; Hong SH; Jung YH; An HJ
    Cancer Res Treat; 2020 Jan; 52(1):277-283. PubMed ID: 31319640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.